Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic stability of remimazolam vs dexmedetomidine during hepatic tumor radiofrequency ablation
KCT0007244Phase 4Not yet recruiting
- Sponsor
- Hana Pharm
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of remimazolam, dexmedetomidine in hepatic neoplasm, sponsored by Hana Pharm. Planned start May 2022; status: not yet recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
hepatic neoplasm
Beyond the preview
Go deeper on KCT0007244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007244.